Bimosiamose API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Bimosiamose API 187269-40-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Bimosiamose. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Bimosiamose
- Synonyms:
- Cas Number:
- 187269-40-5
- DrugBank number:
- DB06197
- Unique Ingredient Identifier:
- 97B5KCW80W
General Description:
Bimosiamose is a chemical compound identified by the CAS number 187269-40-5. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in asthma, psoriasis and psoriatic disorders, atopic dermatitis, inflammatory disorders (unspecified), and chronic obstructive pulmonary disease (COPD). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Classification:
Bimosiamose belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose, classified under the direct parent group Phenolic glycosides. This compound is a part of the Organic compounds, falling under the Organic oxygen compounds superclass, and categorized within the Organooxygen compounds class, specifically within the Carbohydrates and carbohydrate conjugates subclass.
Categories:
Bimosiamose is categorized under the following therapeutic classes: Alkanes, Benzene Derivatives, Carbohydrates, Hexoses, Hydrocarbons, Acyclic, Monosaccharides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Bimosiamose is a type of Anti-asthma
Anti-asthma pharmaceutical APIs are a category of active pharmaceutical ingredients (APIs) specifically developed to combat asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. These APIs play a crucial role in the formulation of effective medications used to manage and treat asthma symptoms.
The primary objective of anti-asthma pharmaceutical APIs is to alleviate airway inflammation and bronchospasms, which are the major factors contributing to asthma attacks. These APIs target specific cellular receptors involved in the inflammatory response, such as leukotriene receptors and beta-2 adrenergic receptors.
Corticosteroids are a common class of anti-asthma APIs used to suppress inflammation in the airways. They work by inhibiting the production of inflammatory molecules, thereby reducing swelling and mucus production. Beta-2 agonists are another essential group of APIs that act on the beta-2 adrenergic receptors in the airway smooth muscles, leading to relaxation and opening of the airways.
Anti-asthma APIs are carefully synthesized and purified to meet stringent quality standards, ensuring their safety and efficacy. Extensive research and development efforts go into optimizing the pharmacological properties of these APIs, including their bioavailability, stability, and compatibility with different formulations.
Pharmaceutical companies utilize anti-asthma APIs to develop various dosage forms, including inhalers, tablets, and injections. These APIs are often combined with other excipients and technologies to enhance drug delivery and improve patient compliance.
In conclusion, anti-asthma pharmaceutical APIs are critical components in the development of medications that effectively manage asthma symptoms. They target key mechanisms underlying asthma pathophysiology, providing relief from airway inflammation and bronchospasms. These APIs enable the formulation of safe and efficient anti-asthma drugs, empowering individuals with asthma to lead healthier lives.
